Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate
Stock Information for Acer Therapeutics Inc.
Please wait while we load your information from QuoteMedia.
More Recent News About Acer Therapeutics Inc.
Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes
Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause
Acer Therapeutics Highlights Key 2022 Achievements and Pipeline Advancements, and Provides Anticipated 2023 Milestones